2017_4q_omron_e
31/57 - Healthcare Zero Cerebral and Cardiovascular Events
【テロップ】
※各テロップ文字をクリックすると該当の場所がピンポイントで閲覧できます。
00:29:51.8
Please see slide 29. First, the three core product categories we will reinforce are home-use BPMs, nebulizers and low-frequency therapy equipment to manage pain. Our aim is to enhance both the quality and the added value of the products. Omron already has top global market share in all 3 products but we believe that by enhancing the value of our products we will be able to increase our market share. Over this four-year period, our objective is to solidify our position as the clear dominant player in all three categories. For example, in mainstay BPMs, we will develop and launch a new product that substantially improves usability. We also aim to capture a significant part of the rapidly expanding online channel in China, as well as roll out compelling new products in promising emerging markets such as India. This should allow us to raise our global market share to more than 55%. In nebulizers, we will launch a new product specifically targeting pediatric asthma. We aim to grow our sales in the growth markets of India, China, as well as South America and Europe. On the back of this, we are targeting a global market share of more than 40%. In low-frequency therapy equipment, we will enhance our marketing activities in Japan and the US, and focus on developing a revolutionary new device. We expect the resulting increase in sales should boost our global market share to over 45%, making us by far the dominant global player. These are the initiatives for reinforcing our three core product categories.
【ノート】